DHR vs BDX vs RGEN Stock Comparison

Danaher, Becton Dickinson and Repligen Prices as of Oct 29, 2026 Peers: Industry group
1 more company in this comparison (A) Create a free account to keep reading and compare up to 10 companies.
DHR Danaher Corp /De/
$236.99 +4.8% 1M +10.7% 1Y
Market cap
$163.63B
P/E
40.9x
Revenue (TTM)
$25.11B
Div. yield
–
Life Sciences Tools Healthcare
6 wins
BDX Becton Dickinson & Co
$198.32 +8.9% 1M +9.3% 1Y
Market cap
$54.28B
P/E
57.7x
Revenue (TTM)
$23.25B
Div. yield
–
Medical Supplies Healthcare
4 wins
RGEN Repligen Corp
$188.64 -3.0% 1M +27.0% 1Y
Market cap
$9.93B
P/E
–
Revenue (TTM)
$805.61M
Div. yield
–
Life Sciences Tools Healthcare
1 win

Head to Head

11 decided of 12

Danaher leads on 6 of the 12 questions below (Danaher 6, Becton Dickinson 4, Repligen 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDHRBDXRGENLeader
Larger companyMarket capitalisation $163.63B $54.28B $9.93B DHR
Cheaper on earningsLower P/E, profitable companies only 40.9x 57.7x -841.6x DHR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.0x 15.3x 97.2x BDX
Faster revenue growthRevenue growth, trailing twelve months +4.6% +17.4% +13.8% BDX
More profitableNet margin, trailing twelve months 15.9% 4.0% — DHR
Better return on capitalReturn on invested capital 5.7% 5.3% — DHR
Less leveragedLower net debt / EBITDA 2.9x 3.2x — DHR
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +10.7% +9.3% +27.0% RGEN
Better 5-year returnAnnualised price return, 5 years -5.3%/yr -3.7%/yr -8.3%/yr BDX
Less volatileAnnualised volatility, 1 year 30.6% 31.8% 46.1% DHR
Higher overall scoreMean of the five percentile scores vs peers 60/100 68/100 57/100 BDX

Percentile Scorecard

DHRBDXRGEN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDHRBDXRGEN
Valuation 70 #70 of 227 90 #23 of 227 42 #132 of 227
Growth 23 #169 of 218 48 #114 of 218 32 #149 of 218
Profitability 88 #26 of 202 80 #42 of 202 69 #63 of 202
Financial Health 46 #127 of 233 28 #168 of 233 84 #39 of 233
Shareholder Returns 77 #31 of 130 95 #8 of 130 –
Overall 60 68 57
  • DHR ranked among 247 companies in Medical Devices and Diagnostics
  • BDX ranked among 247 companies in Medical Devices and Diagnostics
  • RGEN ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDHRBDXRGENSPY
1 month +4.8%+8.9%-3.0% +0.7%
3 months +20.7%+19.8%+31.4% +3.7%
6 months +32.4%+33.1%+59.4% +7.1%
Year to date +3.5%+2.2%+15.1% +12.8%
1 year +10.7%+9.3%+27.0% +11.9%
3 years +28.0%-21.0%+65.2% +85.2%
3 years, per year +8.6%-7.6%+18.2% +22.8%
5 years -24.0%-17.2%-35.1% +67.6%
5 years, per year -5.3%-3.7%-8.3% +10.9%
10 years +203.1%+18.2%+560.0% +262.0%
10 years, per year +11.7%+1.7%+20.8% +13.7%

Risk

MeasureDHRBDXRGENSPY
Volatility, 1Y 30.6%31.8%46.1% 12.7%
Downside volatility, 1Y 31.7%33.1%46.2% 12.6%
Beta vs S&P 500, 1Y 0.450.331.22 1.00
Return / volatility, 1Y 0.350.290.59 0.94
Max drawdown, 5Y -50.8%-50.4%-66.2% -25.4%
From 52-week high -2.1%-5.6%-3.0% -1.2%
52-week high $242.05$210.02$194.57 $779.14
52-week low $161.91$140.71$102.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDHRBDXRGEN
P/E now vs peer median 41.7xmedian 28.7x 57.9xmedian 28.7x -901.6xmedian 28.7x
P/S now vs peer median 6.6xmedian 3.0x 2.3xmedian 3.0x 13.2xmedian 3.0x
EV/EBITDA now vs peer median 24.6xmedian 17.8x 14.1xmedian 17.8x —median 17.8x
P/FCF now vs peer median 30.5xmedian 26.4x 16.9xmedian 26.4x 98.1xmedian 26.4x
P/B now vs peer median 3.2xmedian 2.4x 2.2xmedian 2.4x 5.1xmedian 2.4x
PEG now vs peer median -3.33median 0.99 -3.97median 0.99 31.72median 0.99

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDHRBDXRGEN
Revenue $25.11B $23.25B $805.61M
Gross profit $14.69B $10.91B –
Operating income $5.13B $2.48B $18.24M
Net income $4.00B $941.00M $26.59M
Free cash flow $5.47B $3.20B –
R&D $1.62B $1.37B $56.43M
EPS (diluted) $5.66 $3.42 $-0.21
Cash & equivalents $4.35B $708.00M $726.96M
Total debt $26.56B $72.81B –
Shares (diluted) 707.60M 275.16M 56.64M
Enterprise value $147.44B $51.43B $9.93B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDHRBDXRGEN
P/E 41.7x 57.9x -901.6x
P/FCF 30.5x 16.9x 98.1x
P/Operating cash flow 25.1x 13.7x 82.0x
P/S 6.6x 2.3x 13.2x
P/B 3.2x 2.2x 5.1x
P/Tangible book 5.3x 2.3x 6.0x
EV/EBITDA 24.6x 14.1x –
EV/EBIT 36.8x 28.3x –
EV/Revenue 7.5x 3.0x 13.2x
EV/FCF 34.5x 21.9x –
EV/Operating cash flow 28.5x 17.7x 82.0x
PEG (3Y EPS CAGR) -3.33 -3.97 31.72

Growth

14 metrics
MetricDHRBDXRGEN
Revenue growth (1Y) 4.6% 17.4% 13.8%
Revenue CAGR (3Y) -0.5% 6.9% 7.3%
Gross profit growth (1Y) 2.6% 23.7% –
Gross profit CAGR (3Y) -0.9% 8.5% –
Operating income growth (1Y) 16.1% 13.0% 2,185%
Operating income CAGR (3Y) -7.1% 3.3% -40.5%
Net income growth (1Y) 17.3% -40.6% 1,430%
Net income CAGR (3Y) -14.3% -17.3% -35.9%
EPS growth (1Y) 19.2% -38.0% -777.9%
EPS CAGR (3Y) -12.5% -14.6% -28.4%
Operating cash flow growth (1Y) 7.6% 43.5% -0.8%
Operating cash flow CAGR (3Y) -7.6% 14.5% -4.0%
Free cash flow growth (1Y) 12.4% 54.2% –
Free cash flow CAGR (3Y) -9.0% 22.5% –

Profitability

14 metrics
MetricDHRBDXRGEN
Gross margin 58.5% 46.9% –
EBITDA margin 30.5% 21.4% –
Operating margin 20.4% 10.7% –
Pretax margin 19.0% 8.4% –
Net margin 15.9% 4.0% –
FCF margin 21.8% 13.8% –
Operating cash flow margin 26.4% 17.0% 16.1%
Return on equity 7.6% 3.9% 1.3%
Return on assets 4.5% 1.9% 0.9%
Return on invested capital 5.7% 5.3% –
Return on capital employed 6.4% 6.0% –
Asset turnover 0.3x 0.5x 0.3x
Cash conversion (OCF / net income) 1.7x 4.2x 4.9x
Stock comp / revenue 1.2% 1.2% 4.2%

Financial Health

11 metrics
MetricDHRBDXRGEN
Debt / assets 28.8% 33.1% –
Debt / equity 0.5x 0.7x –
Net debt / EBITDA 2.9x 3.2x –
Debt / FCF 4.9x 5.2x –
Liabilities / assets 43.1% 51.9% 28.5%
Equity / assets 56.9% 48.1% 71.5%
Interest coverage 17.6x 4.2x –
Current ratio 1.7x 0.9x 9.9x
Quick ratio 1.0x 0.3x –
Cash ratio 0.5x 0.1x –
Altman Z-score 3.77 2.30 –

Shareholder Returns

7 metrics
MetricDHRBDXRGEN
Dividend yield 0.6% 2.1% –
Net buyback yield 1.7% 4.6% –
Shareholder yield 2.4% 6.7% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDHRBDXRGEN
Forward P/E 26.0xFY2026 15.3xFY2026 97.2xFY2026
EPS, next fiscal year $9.11FY2026 $12.99FY2026 $1.94FY2026
EPS growth, next FY +16.8%FY2026 +14.8%FY2026 +13.5%FY2026
EPS growth, the year after +8.0% -2.9% +29.4%
Revenue, next fiscal year $27.01BFY2026 $18.11BFY2026 $773.94MFY2026
Revenue growth, next FY +9.9%FY2026 -17.1%FY2026 +4.8%FY2026
Revenue growth, the year after -1.9% +11.6% +35.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDHRBDXRGEN
Held by institutions 81.9% 96.1% 100.0%
Institutions holding 2,118 1,443 483
Change in shares held, QoQ +1.1% +0.6% +1.2%
Institutions buying 840 688 273
Institutions selling 1,015 544 141
Buyers to sellers 0.83 1.26 1.94

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DHRBDXRGEN
DHR 1.00 0.32 0.63
BDX 0.32 1.00 0.27
RGEN 0.63 0.27 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DHR, BDX and RGEN?

Danaher (DHR) is the largest by market capitalisation: Danaher (DHR) $163.63B, Becton Dickinson (BDX) $54.28B, Repligen (RGEN) $9.93B.

Which stock is cheaper, DHR, BDX and RGEN?

Danaher (DHR) trades on the lowest price-to-earnings ratio (Danaher (DHR) 40.9x, Becton Dickinson (BDX) 57.7x, Repligen (RGEN) -841.6x). On next year's consensus earnings, Becton Dickinson (BDX) is cheapest (Danaher (DHR) 26.0x, Becton Dickinson (BDX) 15.3x, Repligen (RGEN) 97.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Becton Dickinson (BDX) grew revenue fastest over the trailing twelve months: Danaher (DHR) +4.6%, Becton Dickinson (BDX) +17.4%, Repligen (RGEN) +13.8%.

Which company is more profitable?

Danaher (DHR) has the highest net margin (Danaher (DHR) 15.9%, Becton Dickinson (BDX) 4.0%). On return on invested capital, Danaher (DHR) leads (Danaher (DHR) 5.7%, Becton Dickinson (BDX) 5.3%).

Which stock has performed better?

Over the past year Repligen (RGEN) returned the most: Danaher (DHR) +10.7%, Becton Dickinson (BDX) +9.3%, Repligen (RGEN) +27.0%. Over five years, Becton Dickinson (BDX) compounded fastest (Danaher (DHR) -5.3%/yr, Becton Dickinson (BDX) -3.7%/yr, Repligen (RGEN) -8.3%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Danaher (DHR) 30.6%, Becton Dickinson (BDX) 31.8%, Repligen (RGEN) 46.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DHR, BDX and RGEN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Danaher (DHR) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.